Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
Nootropic agent. Has a positive effect on the metabolic processes and blood circulation of the brain. Increases the utilization of glucose, improves the flow of metabolic processes, improves microcirculation in ischemic zones, inhibits the aggregation of activated platelets. Has a protective effect in brain damage caused by hypoxia, intoxication, electric shock. Improves the integrative activity of the brain. Does not have sedative and psychostimulating effects.
When ingestion quickly and almost completely absorbed from the digestive tract. C max in the plasma is reached after about 30 minutes, in the cerebrospinal fluid after 2-8 hours. The apparent V d is 0.6 l / kg. Does not bind to blood plasma proteins.
It is distributed in all organs and tissues, penetrates the GEB and the placental barrier. Selectively accumulates in the tissues of the cerebral cortex, mainly in the frontal, parietal and occipital lobes, in the cerebellum and basal ganglia.
T 1/2 from the plasma is 4-5 hours, from the cerebrospinal fluid - 6-8 hours. It is excreted by the kidneys unchanged. With renal failure, T 1/2 increases.
Memory impairment, dizziness, decreased concentration, emotional lability, dementia due to cerebral circulation (ischemic stroke), cerebral trauma, Alzheimer's disease, old age; comatose state of vascular, traumatic or toxic origin; treatment of abstinence and psycho-organic syndrome in chronic alcoholism; learning disabilities in children, not associated with inadequate training or family situation (as part of combination therapy); sickle cell anemia (in combination therapy).
Adults inside - 30-160 mg / kg / day in 2-4 admission. Duration of treatment is 6-8 weeks.
If necessary, apply IM or IV in the initial dose of 10 g / day. With iv administration to patients in serious condition, the daily dose can be 12 g. After clinical improvement, the dose is gradually reduced and switched to oral administration.
Children inside - 30-50 mg / kg / day in 2-3 hours. Treatment should be continued for at least 3 weeks.
From the digestive system: rarely - dyspeptic symptoms, abdominal pain.
From the side of the central nervous system: rarely - nervousness, irritation, irritability, restlessness, sleep disorders, dizziness, headache, tremor; in some cases - weakness, drowsiness.
Other: increased sexual activity.
Hemorrhagic stroke, severe renal failure (with CC <20 ml / min), hypersensitivity to pyracetam.
PREGNANCY AND LACTATION
Adequate and strictly controlled studies of the safety of piracetam use during pregnancy have not been conducted. Use is only possible in cases where the intended benefit to the mother exceeds the possible risk to the fetus.
Pyracetam appears to enter the breast milk. If it is necessary to use during the lactation period, the question of stopping breastfeeding should be solved.
In experimental animal studies, there was no adverse effect of piracetam on the fetus.
APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated in severe renal failure (with CC <20 ml / min).
Use with caution in patients with renal insufficiency. It is recommended that the kidney function is monitored continuously.
Caution is used in patients with severe hemostasis disorder, with large surgical operations and severe bleeding; with renal insufficiency.
It is recommended that the kidney function is monitored continuously.
In case of occurrence of disturbances of a sleep, it is recommended to cancel the evening reception of piracetam, adding this dose to the daytime intake.
A case of interaction of piracetam with simultaneous application with a thyroid extract containing triiodothyronine and tetraiodothyronine is described when anxiety, irritability and sleep disorders were noted in the patient.
With simultaneous use with drugs of thyroid hormones, it is possible to develop central effects - tremor, anxiety, irritability, sleep disorders, confusion.
With the simultaneous use of stimulants of the central nervous system, it is possible to intensify the psychostimulating effect.
With simultaneous use with neuroleptics, there is an increase in extrapyramidal disorders.